The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Investigating the Neuroprotective Potential and Mechanism of Action of an Inhibitor of the Rho-associated Protein Kinase (ROCK)
Study Rationale: Altered signaling through the Rho-associated protein kinase (ROCK) pathway has been found to play a role in the cellular pathogenesis of Parkinson’s disease (PD). Previously, we...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Modulation of Glycine for the Treatment of Parkinson’s Disease
Study Rationale: Levodopa, currently the best treatment for the symptoms of Parkinson’s disease (PD), eventually leads to the development of uncontrollable involuntary movements, called dyskinesia. In...
-
Research Grant, 2021Evaluation of Digital Mobility Data to Identify Individuals at Risk of Developing Parkinson’s Disease
Study Rationale: Gait disturbances play a major role in the motor manifestation of Parkinson’s disease (PD). Traditional clinical assessments aimed at measuring motor deficits do not sufficiently...
-
Fall 2021 RFP: Outcome Measures, 2021Development of Novel Antibodies that Facilitate the Accurate Measurement of All Forms of Alpha-synuclein Present in Biological Fluids
Study Rationale: The ability to accurately detect and quantify alpha-synuclein and its pathology-relevant variants represents a major challenge in Parkinson’s disease (PD). Different studies report...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Impact of TRPML1 Stimulation on Clinical Biomarkers and Synuclein Pathology
Study Rationale: The protein TRPML1 regulates the clearance of cellular debris, including aggregated alpha-synuclein and toxic lipids—a process that is disrupted in Parkinson’s disease (PD). We have...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Development of Small-molecule Inhibitors that Reduce the Aggregation of Tau for the Treatment of Parkinson’s Disease
Study Rationale: The aggregation of alpha-synuclein and tau converts these proteins from a biologically functional state into toxic, fibrous deposits in the brains of people with Parkinson’s disease...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.